Quantcast

Latest cancer therapies Stories

2012-01-30 10:30:04

Researchers at UC Santa Barbara have discovered a molecular pathway that may explain how a particularly deadly form of cancer develops. The discovery may lead to new cancer therapies that reprogram cells instead of killing them. The findings are published in a recent paper in the Journal of Biological Chemistry. The UCSB research team described how a certain mutation in DNA disrupts cellular function in patients with acute myeloid leukemia (AML). The researchers were prompted to study this...

2012-01-27 10:37:38

Cancer is one of the most common causes of death in humans. The conventional cancer therapies include surgery, radiotherapy, chemotherapy, and targeting therapies, which are intended to directly destroy and eliminate tumor cells. These treatments often fail, resulting in tumor metastasis and recurrence. Therefore, there is a critical need for novel cancer therapies. In recent years, an increasing number of studies have revealed that immune responses play a critical role in conventional cancer...

2011-07-21 07:00:00

LOS ANGELES, July 21, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named retired four-star General Merrill A. McPeak to its Board of Directors. General McPeak served nearly four decades in the U.S. Air Force and was USAF chief of staff from 1990 to 1994. The Genesis Biopharma Board now consists of 7 members, including 5 independent directors. "General McPeak has been a distinguished...

2011-07-19 04:00:00

SANTA ROSA, Calif., July 19, 2011 /PRNewswire/ -- Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the latest issue of the peer-reviewed journal, Integrative Cancer Therapies. Lead investigator Dr. Daniel Sliva says, "The formula we studied inhibits growth of highly metastatic human breast cancer cells, and suppresses the metastatic potential of these...

2011-07-18 07:00:00

LOS ANGELES, July 18, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named David Voyticky to its Board of Directors. Mr. Voyticky is currently President of Miller Energy Resources (NYSE: MILL), an oil and gas exploration company, and has more than 16 years of experience in corporate finance and merger and acquisition consulting. The Genesis Biopharma Board now consists of 6 members, including...

2011-07-05 07:00:00

LOS ANGELES, July 5, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced Laszlo Radvanyi, Ph.D., an Associate Professor in the Department of Melanoma Medical Oncology Research at the University of Texas MD Anderson Cancer Center in Houston, has joined its Scientific and Medical Advisory Board. MD Anderson is one of the world's premier cancer centers, conducting advanced research and education programs...

2011-06-28 10:24:00

LOS ANGELES, June 28, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, is holding a conference call with the investment community tomorrow, Wednesday, June 29, 2011 at Noon Eastern (9:00 a.m. Pacific). The Company's Chairman and Chief Executive Officer, Anthony J. Cataldo, will provide an update on the business, and discuss the clinical and commercial development plans for the Company's new autologous cell therapy...

2011-06-22 07:00:00

LOS ANGELES, June 22, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced that it will hold a conference call with the investment community on Wednesday, June 29, 2011 at Noon Eastern (9:00 a.m. Pacific). The Company's Chairman and Chief Executive Officer, Anthony J. Cataldo, will provide an update on the business, and discuss the clinical and commercial development plans for the Company's new...

2011-06-13 07:00:00

LOS ANGELES, June 13, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named Martin Schroeder to its Board of Directors. Mr. Schroeder is a business consultant with more than 30 years of experience advising healthcare companies with regard to corporate strategy, strategic partnerships, marketing and business development, competitive positioning, and mergers and acquisitions. "Martin has...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related